Who is sponsoring NCT00521118?

NCT00521118 is sponsored by Gynecologic Oncology Group.

What drugs are being tested in NCT00521118?

Interventions in NCT00521118: Laboratory Biomarker Analysis, Therapeutic Conventional Surgery.

What condition does NCT00521118 study?

NCT00521118 studies Complete Hydatidiform Mole, Non-Metastatic Gestational Trophoblastic Tumor, Partial Hydatidiform Mole.

Is NCT00521118 still recruiting?

NCT00521118 is currently completed. Last updated 24 August 2017.

Last reviewed 2017-08-24 · How we verify

NCT00521118

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors

Completed Phase 2 Last updated 24 August 2017

What this trial tests

Phase 2 trial testing Laboratory Biomarker Analysis in Complete Hydatidiform Mole in 64 participants. Completed in 25 June 2015.

Timeline

9 October 2007

Primary endpoint
25 June 2015

25 June 2015

Quick facts

Lead sponsor	Gynecologic Oncology Group
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	64
Start date	9 October 2007
Primary completion	25 June 2015
Estimated completion	25 June 2015
Sites	29 locations across Canada, United States

Drugs / interventions tested

Laboratory Biomarker Analysis — full drug profile →
Therapeutic Conventional Surgery

Conditions studied

Complete Hydatidiform Mole — all drugs for Complete Hydatidiform Mole →
Non-Metastatic Gestational Trophoblastic Tumor — all drugs for Non-Metastatic Gestational Trophoblastic Tumor →
Partial Hydatidiform Mole — all drugs for Partial Hydatidiform Mole →

Sponsor

Gynecologic Oncology Group — full company profile →

Who can join

Eligibility, female only, with Complete Hydatidiform Mole or Non-Metastatic Gestational Trophoblastic Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how well a second curettage (removal of the abnormal cancer cells in the uterus using a method of surgically removing the lining of the uterus) works in treating patients with gestational trophoblastic tumors that did not go away after a first curettage (persistent) and has not yet spread to other places in the body (non-metastatic). A second curettage may be effective in treating persistent gestational trophoblastic tumors and may decrease the likelihood that patients will need chemotherapy in the near future.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia.
Osborne RJ, Filiaci VL, Schink JC, Mannel RS, et al · · 2016 · cited 47× · PMID 27500329 · DOI 10.1097/aog.0000000000001554
Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia.
Wang Q, Fu J, Hu L, Fang F, et al · · 2017 · cited 32× · PMID 28892119 · DOI 10.1002/14651858.cd007289.pub3
Advances in diagnostics and management of gestational trophoblastic disease.
Lukinovic N, Malovrh EP, Takac I, Sobocan M, et al · · 2022 · cited 29× · PMID 36286620 · DOI 10.2478/raon-2022-0038
Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia.
Fu J, Fang F, Xie L, Chen H, et al · · 2012 · cited 8× · PMID 23076934 · DOI 10.1002/14651858.cd007289.pub2

Verify or expand the search:

Other trials of Laboratory Biomarker Analysis

Trials testing the same drug.

NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men · withdrawn
NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men · withdrawn
NCT05558904 — An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cance · Phase 1, PHASE2 · recruiting
NCT05564650 — Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome · Phase 1 · active not recruiting
NCT05396859 — Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia · Phase 1 · active not recruiting

Other Gynecologic Oncology Group trials

Trials by the same sponsor.

NCT04393285 — Abemaciclib and Letrozole to Treat Endometrial Cancer · Phase 2 · active not recruiting
NCT03673124 — Ribociclib and Letrozole Treatment in Ovarian Cancer · Phase 2 · active not recruiting
NCT02065687 — Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent · Phase 2, PHASE3 · unknown
NCT01720173 — Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer · Phase 2 · completed
NCT01406769 — Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stag · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00521118 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gynecologic Oncology Group
Last refreshed: 24 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00521118.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing